Table 1 Treatment characteristics of clinical trials included in this study
Study | HBeAg status (+/-) | Strategy for therapy | Primary efficacy measures | Secondary efficacy measures |
|---|---|---|---|---|
Rapti (2007) | - | ADV 10 mg vs. ADV 10 mg + LAM 100 mg | BR, VR | ADV-R, AE |
Chen (2008) | + | ADV 10 mg vs. ADV 10 mg + LAM 100 mg | BR, VR, eAg-C, eAg-SC | No |
Yang (2008) | +/- | ADV 10 mg vs. ADV 10 mg + LAM 100 mg | BR, VR, eAg-C, eAg-SC | ADV-R, AE |
Peters (2004) | + | ADV 10 mg vs. ADV 10 mg + LAM 100 mg | BR, VR, eAg-C, eAg-SC | ADV-R, AE |
Xiao (2008) | + | ADV 10 mg (with or without an overlap period with LAM) vs. ADV 10 mg + LAM 100 mg | BR, VR, eAg-C, eAg-SC | No |
Ijaz (2008) | - | ADV 10 mg vs. ADV 10 mg + LAM 100 mg | VR | ADV-R |